• Suh WW, Johnstone PA, Blackstock AW, Herman J, Konski AA, Mohiuddin M, Poggi MM, Regine WF, Rich TA, Cosman BC, Saltz L, Expert Panel on Radiation Oncology-Rectal/Anal Cancer. Resectable rectal cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2007. 7 p. [16 references]

This is the current release of the guideline.

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

ACR Appropriateness Criteria®

Clinical Condition: Resectable Rectal Cancer

Variant 1: 60-year-old woman with rectal bleeding mass at 5 cm from verge, biopsy positive for adenocarcinoma. Staging workup.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 2: 70 year old woman staged with EUS, a T2NX rectal cancer at 3 cm from verge. Final pathology was T3N1 status post APR. KPS ≥70.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 3: 70-year-old woman staged with EUS, aT2NX rectal cancer at 9 cm from verge, Final pathology was T3N1 status post LAR. KPS ≥70.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 4: 60-year-old woman with circumferential lesion at 8 cm from verge. EUS stage T3N1. KPS ≥70.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 5: 45-year-old woman with EUS staged T3N0, 4 cm lesion at 3 cm from verge. KPS ≥70.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Summary of Literature Review

In what arguably may be the most pivotal recent trial in the area of resectable rectal cancer management, a randomized trial from Germany has established a regimen of preoperative chemoradiotherapy and surgery followed by additional cycles of chemotherapy alone as the standard of care for clinical stages T3 or T4, or for node-positive rectal cancer. Other clinical studies from the United States, Europe, and Asia have also influenced the treatment strategies of operable rectal cancer, as various approaches using preoperative or postoperative radiotherapy, with or without chemotherapy, have been examined. A summary of the major randomized clinical trials spanning the past several decades is provided below.

Postoperative Radiotherapy with or without Chemotherapy

Several classic trials have examined the use of postoperative irradiation alone or in combination with chemotherapy; in three of these (GITSG, NCCTG, Norway), radiotherapy delivered with concurrent chemotherapy improved both local control and survival.

The method of administration of chemotherapy appears to be important in obtaining optimal results. Infusional 5-FU was found to be superior to bolus 5-FU and is considered to be a standard adjuvant therapy; more recent studies have investigated alternate means of optimizing chemotherapy. The timing of early versus late radiotherapy with respect to chemotherapy may also be important according to the preliminary results of a recent randomized study and warrants further investigation.

Preoperative Radiotherapy with or without Chemotherapy

Exploring the role of preoperative radiotherapy alone (25 Gy in 5 fractions), a Swedish trial showed improvements in both local control and survival. However, given its long-term treatment toxicity and the inability to combine the hypofractionated radiotherapy regimen with systemic chemotherapy, this approach is rarely used. More importantly, three recent trials from Europe have examined the role of incorporating concurrent chemotherapy with preoperative irradiation using standard radiotherapy fractionation, in keeping with the postoperative combined chemoradiotherapy model. Two studies (European Organisation for Research and Treatment of Cancer [EORTC] 22921, Fondation Française de Cancérologie Digestive [FFCD] 9203) demonstrated a significant improvement in local control, in the absence of a survival or sphincter-preservation benefit, with the addition of chemotherapy. The third trial from Poland reported no differences with respect to local control, survival, or late toxicity between the two arms. As expected, acute toxicity was increased with the addition of chemotherapy, as had been noted in the French trial (FFCD 9203).

Preoperative versus Postoperative Chemoradiotherapy

The important question of comparing preoperative versus postoperative chemoradiotherapy, as noted above, was addressed by a randomized trial from Germany. The preoperative regimen was associated with significantly improved local control and increased sphincter-preservation rates with no differences in disease-free or overall survival. It also resulted in decreased rates of acute and chronic treatment toxicity, when compared to the postoperative approach. Another randomized trial (National Surgical Adjuvant Breast and Bowel Project [NSABP] R03) exploring the same question in the United States was terminated early due to poor accrual. However, it did show a trend towards improved survival; clinical response to the preoperative therapy was associated with significantly improved disease-free and overall survival. The current standard of care in the United States is, therefore, to provide preoperative chemoradiotherapy, using standard radiotherapy fractionation and concurrent fluorouracil for clinical stages T3 or T4, or for node-positive rectal cancer.

Need for Future Trial

Despite the published data from randomized trials that support the shift to preoperative chemoradiotherapy, a subset of patients will require surgical resection upfront for a variety of clinical reasons. A pooled analysis of five randomized clinical trials in the United States suggests clinical reasons. A pooled analysis of five randomized clinical trials in the United States suggests that not all patients with resected tumors may require a trimodality (surgery, chemotherapy, radiotherapy) treatment approach. Patients with favorable or "intermediate-risk" (T3N0 or T1-2N1) tumors were found to have benefited equally from either postoperative chemoradiotherapy or chemotherapy alone. A future clinical study is warranted to validate the appropriateness of such a risk-adapted treatment-minimization strategy.

Abbreviations

• AP/PA, anteroposterior/posteroanterior
• APR, abdominoperineal resection
• CBC, complete blood count
• CEA, carcinoembryonic antigen
• CT, computed tomography
• EUS, endoscopic ultrasound
• IMRT, intensity modulated radio therapy
• INV, invasive
• KPS, Karnofsky performance scale
• LAR, low anterior resection
• MRI, magnetic resonance imaging
• PET, positron emission tomography
• RT, radiotherapy
• US, ultrasound

None provided

The recommendations are based on analysis of the current literature and expert panel consensus.

• Suh WW, Johnstone PA, Blackstock AW, Herman J, Konski AA, Mohiuddin M, Poggi MM, Regine WF, Rich TA, Cosman BC, Saltz L, Expert Panel on Radiation Oncology-Rectal/Anal Cancer. Resectable rectal cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2007. 7 p. [16 references]

Not applicable: The guideline was not adapted from another source.

2007

American College of Radiology - Medical Specialty Society

The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria®.

Committee on Appropriateness Criteria, Expert Panel Radiation Oncology-Rectal/Anal Cancer

Panel Members: W. Warren Suh, MD; Peter A. Johnstone, MD; A. William Blackstock, MD; Joseph Herman, MD, MSc; Andre A. Konski, MD; Mohammed Mohiuddin, MD; Matthew M. Poggi, MD; William F. Regine, MD; Tyvin A. Rich, MD; Bard C. Cosman, MD; Leonard Saltz, MD

Not stated

This is the current release of the guideline.

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

None available

This NGC summary was completed by ECRI Institute on December 17, 2007.